文献速递淋巴瘤造血干细胞移植与细胞治疗

侵袭性B细胞淋巴瘤患者抗CD19 CAR-T细胞治疗失败后的结局:DESCAR-T分析

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.
PubMed 文献 · Blood · 2022-01-01

在法国DESCAR-T注册研究中,550例接受抗CD19 CAR-T治疗的侵袭性B细胞淋巴瘤患者中238例(43.3%)出现进展/复发,中位随访7.9个月。失败后中位无进展生存期2.8个月、中位总生存期5.2个月;D0-D30内失败者中位总生存期1.7个月,显著短于D30后失败者的3.0个月(P=0.0001)。多因素分析显示输注时高乳酸脱氢酶、CAR-T失败时间小于D30及输注时高C反应蛋白是总生存期的预测因素。

要点

  • DESCAR-T注册研究中43.3%(238/550)的患者在CAR-T治疗后出现进展/复发。
  • 失败后中位总生存期5.2个月,D0-D30内失败者仅1.7个月。
  • 失败后仅18.9%的极早期失败患者存活至6个月。

核心结论

  • 这项多中心分析证实CAR-T细胞治疗后复发患者结局不佳,凸显需要针对该人群的进一步策略。

研究设计与样本

  • 基于法国DESCAR-T注册研究的多中心分析,纳入550例接受抗CD19 CAR-T细胞治疗的侵袭性B细胞淋巴瘤患者,其中238例(43.3%)出现进展/复发,中位随访7.9个月。

主要发现

  • 失败后154例(64%)接受挽救治疗:38.3%接受来那度胺,7.1%接受双特异性抗体,21.4%接受靶向治疗,11%接受放疗,20%接受多种方案的免疫化疗。
  • 失败后中位无进展生存期2.8个月,中位总生存期5.2个月。
  • D0-D30内失败者中位总生存期1.7个月,D30后失败者3.0个月(P=0.0001)。
  • 47.9%的患者在6个月时存活,但极早期失败后仅18.9%存活。
  • 多因素分析中总生存期的预测因素为输注时高乳酸脱氢酶、CAR-T失败时间小于D30及输注时高C反应蛋白。

关键数值与推荐

  • 注册时57.0%的患者年龄校正国际预后指数为2至3,18.9%东部肿瘤协作组体能状态评分≥2,57.1%在CAR-T前接受超过3线治疗,87.8%接受桥接治疗。
  • 输注时66%的患者为进展性疾病,38.9%有高乳酸脱氢酶。
  • CAR-T治疗失败发生于中位2.7个月(范围0.2-21.5个月);54例(22.7%)为极早期失败(第0-30天),102例(42.9%)为早期失败(第31-90天),82例(34.5%)为晚期失败(大于第90天)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a major advance in the treatment of relapsed/refractory aggressive B-cell lymphomas. However, a significant number of patients experience failure. Among 550 patients registered in the French registry DESCAR-T, 238 (43.3%) experienced progression/relapse, with a median follow-up of 7.9 months. At registration, 57.0% of patients presented an age-adjusted International Prognostic Index of 2 to 3, 18.9% had Eastern Cooperative Oncology Group performance status ≥2, 57.1% received >3 lines of treatment prior to receiving CAR T-cells, and 87.8% received bridging therapy. At infusion, 66% of patients presented progressive disease, and 38.9% had high lactate dehydrogenase (LDH). Failure after CAR T-cell treatment occurred after a median of 2.7 months (range: 0.2-21.5). Fifty-four patients (22.7%) presented very early failure (day [D] 0-D30); 102 (42.9%) had early failure (D31-D90), and 82 (34.5%) had late (>D90) failure. After failure, 154 patients (64%) received salvage treatment: 38.3% received lenalidomide, 7.1% bispecific antibodies, 21.4% targeted treatment, 11% radiotherapy, and 20% immunochemotherapy with various regimens. Median progression-free survival was 2.8 months, and median overall survival (OS) was 5.2 months. Median OS for patients failing during D0-D30 vs after D30 was 1.7 vs 3.0 months, respectively (P = .0001). Overall, 47.9% of patients were alive at 6 months, but only 18.9% were alive after very early failure. In multivariate analysis, predictors of OS were high LDH at infusion, time to CAR-T failure <D30, and high C-reactive protein at infusion. This multicentric analysis confirms the poor outcome of patients relapsing after CAR T-cell treatment, highlighting the need for further strategies dedicated to this population.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Di Blasi R, Le Gouill S, Bachy E, et al. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood. 2022. PMID: 36122385. doi:10.1182/blood.2022016945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。